SCHEMBL24901672

SCHEMBL24901672

COC(=O)c1cc(F)c([N+](=O)[O-])c(C2CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.42
LMNA P02545 2/20 0.42
AHR P35869 1/20 0.42
SLC6A3 Q01959 1/20 0.39
POLB P06746 3/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 2/20 0.38
NFKB1 P19838 1/20 0.38
XDH P47989 1/20 0.38
GFER P55789 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
FUT7 Q11130 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 2/20 0.37
VCAM1 P19320 1/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309765 0.84 KDM4E (0.48) LMNAPOLBKDM4EGAANFKB1
SCHEMBL22689342 0.81 HPGD (0.47) HPGDLMNAAHRPOLBKDM4E
SCHEMBL26970977 0.80 POLB (0.42) LMNAPOLBKDM4EGAANFKB1
SCHEMBL31160144 0.79 PDE5A (0.40) HPGDLMNAAHRPOLBKDM4E
SCHEMBL27176959 0.79 POLB (0.56) LMNAPOLBKDM4EGAANFKB1
SCHEMBL31463421 0.79 POLB (0.56) LMNAPOLBKDM4EGAANFKB1
SCHEMBL25320756 0.79 KMT2A (0.45) LMNAPOLBKDM4EGAANFKB1
SCHEMBL27362105 0.79 KDM4E (0.45) HPGDLMNAPOLBKDM4EGAA
SCHEMBL31123060 0.77 NOTUM (0.43) LMNAPOLBKDM4EGAANFKB1
SCHEMBL29159760 0.77 POLB (0.44) LMNAPOLBKDM4EGAANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382471-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF Hepagene Therapeutics (HK) Limited (CN) 2024-11-21 US disclosed
EP-4373821-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF Hepagene Therapeutics (HK) Limited (HK) 2024-05-29 EP disclosed
CN-117715906-A Glucagon-like peptide-1 receptor modulators and uses thereof 和博医药有限公司 2024-03-15 CN disclosed
WO-2023001237-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF Hepagene Therapeutics (HK) Limited (CN) 2023-01-26 WO disclosed
WO-2023001237-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF Hepagene Therapeutics (HK) Limited (CN) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382471-A1 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF GLP1R, GIPR, GCGR HPGD 1920/4885LMNA 3533/4885AHR 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.